Articles, papers and letters by Anthony Cox. Links given when available.
Anton C, Cox AR, Ferner RE, Memory loss and confusion with statins – an analysis of spontaneous case reports using the DoTS classification scheme. Drug Safety 2008;31 (10): 911 (Presented at the 8th Annual Meeting of ISoP Buenos Aires – Argentina, 5th-8th October 2008)
Cox AR, Phull S, Price V, Anton C, Hebron B, Langford NJ, Ferner RE. Retrospective analysis of pharmacy dispensing errors: Twelve years experience in a UK Hospital. Drug Safety; 31 (10): 949 (Presented at the 8th Annual Meeting of ISoP Buenos Aires – Argentina, 5th-8th October 2008)
Cox AR, Wood KMG, Marriott JF, Ferner RE. Causality and definitions: How general practitioners decide what to report to spontaneous reporting schemes. Pharmacoepidemiology and Drug Safety 2008;17(1):S164 (Presented at the 24th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Copenhagen, Denmark, 17-20 August 2008)
Cox A, Layton D. Adverse drug reactions: Neuropsychiatric drug reactions associated with varenicline (Champix). The Pharmaceutical Journal 2008;281:129
Cox AR. Assessing, managing and reporting adverse drug reactions may better equip us to minimise medicines-related harm. Pharmacy in Practice 2008;18(2):57-61
Cox AR, Kirkham H. A Case Study of a Graphical Misrepresentation: Drawing the Wrong Conclusions about the Measles, Mumps and Rubella Virus Vaccine. Drug Safety 2007; 30(10): 831-836.
Cox AR, Anton C, Marriott JF, Ferner RE. The paradox of low prescribers who are high reporters: correlates of spontaneous reporting of adverse drug reactions within primary care. Drug Safety 2007; 30(10): 977-978
(Presented at the 7th Annual Meeting of ISoP Bournemouth – UK, 21-24 October 2007)
Layton D, Cox A. Pharmacovigilance. In: Bond C editor. Using Medicines Information. Oxford, Radcliffe Publishing 2007. p. 141-168.
Langford NJ, Cox A. Interactions between Antihypertensive Drugs and Other Medications. In: Comprehensive Hypertension. Editors: Lip GHY, Hall JE. Philadelphia, Mosby Elsevier; 2007. 1075-1086.
Cox A. Chimeraphobia. The Philosophers’ Magazine 2007; 38: 14-16
Cox A, McDowell S. Changing roles, changing risks — the paradox of pharmacist prescribing. The Pharmaceutical Journal. 2007; 278: 46. [text]
Cox AR. Serious ADRs Recognition and management of drug-induced blood disorders. Prescriber 2007; 18 (3) :51-56.
Anton C, Cox AR, Coleman JJ, Ferner RE. A Comparison of Publically Available Spontaneous Adverse Drug Reaction Data from National Spontaneous Reporting Schemes. Drug Safety 2006; 29(10): 914 (Presented at the 6th Annual Meeting of ISoP Li̬ge РBelgium, 11-13 October 2006) [poster]
Anton C, Cox AR, Ferner RE. Targetted Follow-Up of Spontaneous ADR Reports to Improve Follow-Up Rates. Drug Safety 2006; 29(10):996
(Presented at the 6th Annual Meeting of ISoP Li̬ge РBelgium, 11-13 October 2006) [presentation]
Cox AR, Marriott JF, Wood KMG, Ferner RE. General Practitioners’ Attitudes towards
Adverse Drug Reaction Reporting: A Qualitative Study. Drug Safety 2006; 29(10):952 (Presented at the 6th Annual Meeting of ISoP Li̬ge РBelgium, 11-13 October 2006) [poster]
Cox AR, Higham C, Chandler ML, Situnayake RD. Methotrexate: Patient Knowledge of Key Safety Issues. Pharmacoepidemiology and Drug Safety 2006; 15: S288
(Presented at the 22nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, August 24-27, 2006 Lisbon, Portugal) [poster]
Cox AR. Prevention and management of drug-induced ocular disorders. Prescriber 2006:17(12): 39-42 [PDF]
Cox A, Langford N. Partisan editorials serve no one, least of all new prescribers. Pharmaceut J 2006; 276: 621 [text]
Casiday RE, Cox AR. Restoring confidence in vaccines by explaining vaccine safety monitoring : is a targeted approach needed? Drug Safety 2006; 29(12): 1105-9 [abstract]
Cox AR. Lessons from TGN1412. Prescriber 2006;17:9 [PDF version]
Ferner RE, Langford NJ, Cox AR. Testamentary capacity. In Payne-James J, Byard R, Corey T, Henderson C. editors. Encyclopedia of Forensic and Legal Medicine. New York: Academic Press; 2005. p252-258. [Link]
Cox AR. Yellow Card Reporting Scheme: What to report and where to? Tomorrow’s Pharmacist. 2005: 66-67.
Cox AR. New Edition affirms place as key text in the area of pharmacovigilance. The Pharmaceutical Journal. 2004;272:393
Cox AR, Langford N. BANs to rINNS. Journal of Clinical Pharmacy and Therapeutics. 2004;29:491-495
Cox AR, Marriott JF, Wilson KA, Ferner RE. Adverse drug reaction teaching in UK undergraduate medical and pharmacy programmes. Journal of Clinical Pharmacy and Therapeutics. 2004;29:31-35
Cox AR, Marriott JF, Wilson KA, Ferner RE. Message from the top: chief pharmacists’ views of adverse drug reaction reporting. International Journal of Pharmacy Practice. 2004;12(suppl):R68
Cox AR. Colchicine in acute gout: Optimal dose of colchicine is still elusive. BMJ, Jan 2004; 328: 288. [text]
Cox AR, Langford N. Drug-induced cardiac failure. Adverse Drug Reaction Bulletin. 2003;220:843-846.
Anton C, Cox AR, Watson RDS, Ferner RE. The safety of spironolactone treatment in patients with heart failure. Journal of Clinical Pharmacy & Therapeutics. 2003;28(4):285-287. [Abstract]
Cox AR, The war on the web: Googlebomb of mass destruction. The Guardian. 10th July 2003.[text]
Kerr KL, Higham C, Cox AR, Situnayake RD. A determination of patient awareness of the safety issues surrounding treatment with methotrexate. The Pharmaceutical Journal 2003;271:900-901. [PDF]
Cox AR. Let us be called the Royal Society of Pharmacists of Great Britain. The Pharmaceutical Journal 2003;271:44. [text] [PDF]
Cox AR. Manufacturers should make reading labels easier. The Pharmaceutical Journal 2003;270:514. [text]
Cox AR, Anton C. Report [...] drug reactions with warfarin. The Pharmaceutical Journal 2003;270:366-367. [text]
Cox AR. Advertising: Prescribers need appraisal training programmes. The Pharmaceutical Journal 2003;270:154. [text]
Whitaker S, Cox AR, Alexander AM. Internet networking for pharmacists: an evaluation of a mailing list for UK pharmacists. International Journal of Pharmacy Practice. 2003;11:25–32. [Abstract]
Anton CA, Cox AR, Ferner RE. Using trade names: sometimes it helps. Archives of Internal Medicine 2003 ;162: 2636.
Cox AR, Dent SN. Warfarin: Risks not always easy to evaluate.British Medical Journal Electronic response [text]
Anton C, Cox AR. More data are needed. British Medical Journal Electronic response [text]
Dent SN, Cox AR, Marriott JF, Langley CA, Wilson KA. Warfarin toxicity: do discharge ICD-codes and yellow cards accurately identify serious adverse drug reactions? The International Journal of Pharmacy Practice. 2002;10(suppl):R40. [PDF]
Cox AR. Systemic effects of ocular drugs. Adverse Drug Reaction Bulletin. 2002;215:823-826.
Langford NJ, Cox AR. Medication errors: Over reliance on any safety system is not ideal. The Pharmaceutical Journal.2002;269:248. [text]
Rippengill KL, Higham C, Cox Ar, Situnayake RD. Methotrexate – patient awareness and safety issues. Pharmacy World & Science. 2002;24(3):A21.
Cox AR. Embracing ADR reporting could improve pharmacists’ standing.The Pharmaceutical Journal 2002;269:14.[text] [PDF]
Cox A, Jenkins A. A case of carboplatin hypersensivity. Pharmacy in Practice 2002;12(5):187.
Cox A, Millane T. An adverse drug reaction as a consequence of error. Pharmacy in Practice 2002;12(2):84-86.
Cox AR, Marriott JF. Take a spoonful of sugar with salt. The Hospital Pharmacist 2002;9(4):90.[text]
Cox A. Childhood vaccination, a social responsibility. The Pharmaceutical Journal 2002;268:570.[text]
Cox A, Book Review – Martindale 33rd edition.The Pharmaceutical Journal 2002; 268 :505.[text]
Cox A, Overwhelming evidence for safety of MMR. The Pharmaceutical Journal 2002;268:398. [text]
Cox AR. Marriott JF. Safety First. Pharmaceutical Marketing February 2002 [text]
Jenkins A, Cox A. Influenza vaccine and warfarin. Pharmacy in Practice 2002;12(1) :140.
Cox A. Humans are fallible machines. British Medical Journal Electronic response [text]
Cox A. Syncope as a possible adverse drug reaction. Pharmacy in Practice 2001;11(9):286.
Cox A, Underhill J. New Drugs must be prescribed judiciously. The Pharmaceutical Journal 2001;267 :646-647.[text]
Cox A. What about side effects and contraindications? The Pharmaceutical Journal 2001;267:425.[text]
Cox A, Anton C. Safety profile of bupropion for chronic obstructive pulmonary disease. The Lancet 2001;358:1010.
Cox A, Anton C, Goh CHF, Easter M, Langford NJ, Ferner RE. Adverse drug reactions in patients admitted to hospital indentified by discharge ICD-10 codes and by spontaneous reports. British Journal of Clinical Pharmacology 2001;52:337-339.
Bradley M.J, Cox A. Suspected interaction betweeen celecoxib and warfarin. Pharmacy in Practice 2001;11(8):243-245.
Anton C, Cox A. In some respects, yes. British Medical Journal Electronic response [text]
Anton C, Cox A. Adverse Drug reactions. British Journal of General Practice. 2001;51(468):582-683.[text]
Cox A, Anton C, Ferner R. Take care with Zyban. The Pharmaceutical Journal. 2001;266:718-722.[text]
Cox AR, Marriott J. Is self-checking (by anyone) a risk too far? The Pharmaceutical Journal 2001;266:814.[text]
Cox AR. Hypokalaemia associated with the use of spironolactone in heart failure. Pharmacy in Practice. 2001;11(6):187-189.
Cox AR, Barnett AL. Reporting reactions to newly marketed drugs. Pharmacy in Practice. 2001;11(4):121-122.
Mundia AN, Cox AR, Marriott JF. Discordance: coronary care patient’s knowledge of Medicines. GHP . 2001;2(2):14.
Cox AR. What can hospital pharmacy do to increase adverse drug reaction reporting. Pharmacy in Practice 2001;11(3):84.
Cox AR. Haematoma associated with tirofiban and enoxaparin in an unstable angina patient.Pharmacy in Practice 2001;11(3):87-88.
Cox AR. Adverse reactions to intra-vascular radiological contrast media. Pharmacy in Practice 2001;11(2):54-55.
Cox AR, McCarthy J. Hepatic adverse drug reactions. Pharmacy in Practice. 2000;11(1):18-19.
Cox AR, Fox H. Split and merge: a way forward for the Royal Pharmaceutical Society. The Pharmaceutical Journal 2000;265:263.[text]
Cox AR, Barrett J. Identifying adverse drug reactions in the ICU. Pharmacy in Practice 2000;10(9):322-4.
Cox AR, Townsend T. Reporting well-known reactions. Pharmacy in Practice 2000;10(8): 288-90.
Cox AR. Elite II: Caution required. The Pharmaceutical Journal. 2000;263:858.[text]
Cox AR. The pharmacist’s role in adverse drug reactions. Pharmacy in Practice 2000;10(7): 262-3.
Cox AR. The Committee on Safety of Medicine’s Yellow Card Scheme. Pharmacy in Practice 2000;10(6):213-15.
Cox AR, Marriott J. Dealing with dispensing errors. The Pharmaceutical Journal 2000;264:724.[text]
Cox AR. Pharmacovigilance: Why reports are anonymous. The Pharmaceutical Journal 1999;263:784.[text]
Other articles and letters
Cox AR. The Society: Membership approval The Pharmaceutical Journal 2003;271:175.[text]
Cox AR. An opportunity to move forward. The Pharmaceutical Journal. 2003;270:858.[text]
Cox A. The Society: Knocking down a straw man.The Pharmaceutical Journal. 2002;269:100.[text]
Cox A. A way forward for the Society? Pharmacy Magazine. 2002;June issue:8
Cox A. Time to bring clarity to the representation debate The Pharmaceutical Journal 2002;268:140.[text]
Cox A. Access to reports of the statutory committee. The Pharmaceutical Journal 2001;267:321-324.[text]
Cox A. Leadership requires listening. The Pharmaceutical Journal. 2001;266:852-856.[text]
Fox HR,Cox AR. Some changes are inevitable. The Pharmaceutical Journal. 2001;265:855.[text]
Cox AR. Finance concern. The Pharmaceutical Journal. 2000;265:754.[text]
Cox AR. Parish Magazine. The Pharmaceutical Journal. 2000;265:443.[text]
Whitaker S, Cox AR, Alexander A. The members, the medium and the message; an evaluation of Private-Rx, the Information Network for UK Pharmacists. Pharm J 2000; 265: R75
Alexander A, Cox AR, Whitaker S. Net gains; the contribution of an Internet mailing list to continuing professional development for pharmacists. Presented at the Lifelong Learning Conference, Belfast, 2000
Alexander A, Cox AR, Whitaker S. Methodological aspects of the use of the internet for survey research. Presented at the Primary Care research Networks Conference, Brighton, 2000
Fox HR, Cox AR. Separation of functions. The Pharmaceutical Journal. 2000;265:394.[text]
Cox AR. e-pharmacy: ethereal pharmacy? Chemist and Druggist 2000;30 September 2000:8
Whitaker S, Cox AR, Alexander AM The members, the medium and the message: an evaluation of Private-Rx, the information network for UK pharmacists. The Pharmaceutical Journal 2000;265:R73. (suppl British Pharmaceutical Conference, Birmingham) [text]
Cox AR. Breaking the deadlock. The Pharmaceutical Journal. 2000; 265:363.[text]
Cox AR, Whitaker S. Protecting the legacy. The Pharmaceutical Journal. 2000;265:160.[text]
Cox AR. Cat Mat Publicity. The Pharmaceutical Journal. 2000;264:655.[text]
Nebrensky C, Cox AR, Burgess P, Haynes S, Wong LS, Young J, et al.. Who authorised flat purchase? The Pharmaceutical Journal. 2000;264 :589.[text]
Phillips G, Cox AR, Eyles R, Fox H, Whitaker S, Curtis S, et al.. More details please. The Pharmaceutical Journal. 2000;264:402-403.[text]
Cox AR. Electing the Council. The Pharmaceutical Journal. 1999;263:349. [text]